DRAGAN GRABULOVSKI

Dragan Grabulovski is a distinguished Venture Partner at Pureos Bioventures, a leading venture capital firm dedicated to investing in the next generation of life science companies. In his pivotal role, Dragan leverages a profound understanding of drug discovery and development, coupled with significant entrepreneurial experience, to identify and support groundbreaking ventures. His expertise is instrumental in Pureos Bioventures' mission to back innovative biotech firms poised to make a substantial impact on human health.

At Pureos Bioventures, Dragan's investment focus areas are primarily within the early-stage life sciences sector. He is particularly interested in novel therapeutic modalities, platform technologies, and companies developing solutions for unmet medical needs. His deep scientific acumen allows him to conduct thorough due diligence, evaluating the scientific merit and commercial potential of prospective investments. He actively contributes to the strategic development and growth of portfolio companies, providing guidance on R&D, clinical development, and business strategy.

Dragan's impressive career background underpins his success as a venture partner. He holds a Ph.D. in Biochemistry from ETH Zurich and completed postdoctoral research at Harvard Medical School. This strong academic foundation paved the way for a career marked by significant contributions to the biotech industry. Notably, Dragan was a co-founder and Chief Scientific Officer of Covagen AG, a Swiss biotech company specializing in multispecific biologics, which was successfully acquired by Cilag GmbH, a Johnson & Johnson company. Following the acquisition, he continued to contribute to Johnson & Johnson, serving as Head of Biologics Research at Actelion Pharmaceuticals, further solidifying his expertise in biologics drug discovery and development. His journey from academic research to successful entrepreneurship and corporate leadership provides him with a unique perspective on the challenges and opportunities within the biotech ecosystem.

While specific individual investments are part of Pureos Bioventures' collective portfolio, Dragan's influence is evident in the firm's strategic choices and the scientific rigor applied to its investments. His track record of building and leading successful biotech ventures makes him an invaluable asset to Pureos Bioventures and its portfolio companies. He is committed to fostering innovation and translating scientific breakthroughs into tangible patient benefits, making him a key figure in the European biotech venture capital landscape.